about
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
P50
description
researcher
@en
name
Hitomi Morishima
@en
type
label
Hitomi Morishima
@en
prefLabel
Hitomi Morishima
@en
P31
P496
0000-0001-8118-1197